Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.
Neutralizing and non-neutralizing antibodies to linear epitopes on HIV-1 envelope glycoproteins have potential to mediate antiviral effector functions that could be beneficial to vaccine-induced protection. Here, plasma IgG responses were assessed in three HIV-1 gp120 vaccine efficacy trials (RV144,...
שמור ב:
| Principais autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Public Library of Science (PLoS)
2013-01-01
|
| סדרה: | PLoS ONE |
| גישה מקוונת: | http://europepmc.org/articles/PMC3784573?pdf=render |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
